Enveric Biosciences, Inc.
ENVB
$6.11
$0.071.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.04% | 11.07% | 8.19% | 26.16% | 70.43% |
| Total Depreciation and Amortization | -52.83% | -5.15% | -2.37% | -11.48% | -25.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -41.23% | -42.05% | -36.66% | 243.66% | -76.24% |
| Change in Net Operating Assets | 126.48% | 14.01% | 326.29% | 188.14% | -584.61% |
| Cash from Operations | 34.58% | 7.96% | 25.10% | 66.17% | 35.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 596.28% | -10.75% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 89.04% | 99.99% | -- |
| Cash from Financing | 1,205.52% | -33.18% | 349.01% | 593.05% | 103.27% |
| Foreign Exchange rate Adjustments | -376.92% | -148.15% | 45.41% | -39.54% | -93.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.37% | -49.52% | 55.99% | 86.11% | 47.93% |